These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38326910)

  • 1. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
    Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
    Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
    Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
    Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
    Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome.
    Na JC; Nagaya N; Rha KH; Han WK; Kim IY
    Clin Genitourin Cancer; 2019 Aug; 17(4):299-305.e1. PubMed ID: 31204211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the prognostic significance and molecular characteristics of tumor-infiltrating B lymphocytes in clear cell renal cell carcinoma through a comprehensive bioinformatics analysis.
    Yue Y; Cai X; Lu C; Sechi LA; Solla P; Li S
    Front Immunol; 2023; 14():1238312. PubMed ID: 37908350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
    Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
    Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
    Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma.
    Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL
    Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of prognostic and tumor microenvironment characteristics of necroptosis index and BIRC3 in clear cell renal cell carcinoma.
    Wei K; Zhang X; Yang D
    PeerJ; 2023; 11():e16643. PubMed ID: 38130918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
    Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
    BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of necroptosis-related lncRNA signature with potential implications in tumor heterogeneity and prediction of prognosis in clear cell renal cell carcinoma.
    Lin H; Qu L; Chen G; Zhang C; Lu L; Chen Y
    Eur J Med Res; 2023 Jul; 28(1):236. PubMed ID: 37452355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Analysis Reveals Novel Specific Metastatic Mutations in Chinese Clear Cell Renal Cell Carcinoma.
    Meng H; Jiang X; Cui J; Yin G; Shi B; Liu Q; Xuan H; Wang Y
    Biomed Res Int; 2020; 2020():2495157. PubMed ID: 33062672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
    Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
    Front Immunol; 2022; 13():869297. PubMed ID: 35936012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.